Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03262727 · ClinicalTrials.gov registry record · Phase 1
The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT03262727 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 49 participants.
The verdict
NCT03262727, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the effect of BMS-986165 in combination with an oral contraceptive in healthy female patients.
Interventions
- DRUG BMS-986165
- DRUG Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2017-09-01 |
| Est. Completion | 2017-12-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03262727
The ClinicalTrials.gov registry entry for NCT03262727 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BMS-986165 is the first listed.
NCT03262727 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03262727 about?
NCT03262727 is a clinical study titled "The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients". The purpose of this study is to investigate the effect of BMS-986165 in combination with an oral contraceptive in healthy female patients.
What is the current status of trial NCT03262727?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2017-09-01. Estimated completion is 2017-12-19.
What interventions are being tested in trial NCT03262727?
The interventions under investigation include: BMS-986165 (DRUG), Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol) (DRUG).
Who is sponsoring clinical trial NCT03262727?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.